Opportunities and Challenges of Generic Pre-Exposure Prophylaxis Drugs for HIV

Jeromie Ballreich, Timothy Levengood, Rena M. Conti

Research output: Contribution to journalArticlepeer-review


Antiretroviral pre-exposure prophylaxis (PrEP) is protective against HIV. Low utilization rates amongst HIV vulnerable populations are due in part to the high cost of PrEP. Generic PrEP offers the potential to improve health at significantly reduced costs. In this study, we examine early utilization patterns and prices for generic PrEP. We discuss the opportunities and challenges for generic PrEP to improve health among HIV vulnerable populations.

Original languageEnglish (US)
Pages (from-to)32-39
Number of pages8
JournalJournal of Law, Medicine and Ethics
Issue numberS1
StatePublished - 2022


  • Drug Policy
  • Drug Pricing
  • HIV
  • PrEP

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Opportunities and Challenges of Generic Pre-Exposure Prophylaxis Drugs for HIV'. Together they form a unique fingerprint.

Cite this